Cell-free bioproduction of b-cryptoxanthin and zeaxanthin
US-2024368663-A1 · Nov 7, 2024 · US
US10344267B2 · US · B2
| Field | Value |
|---|---|
| Publication number | US-10344267-B2 |
| Application number | US-201415100065-A |
| Country | US |
| Kind code | B2 |
| Filing date | Nov 26, 2014 |
| Priority date | Nov 27, 2013 |
| Publication date | Jul 9, 2019 |
| Grant date | Jul 9, 2019 |
A practical reading order for non-experts. Skip the full description unless you need deep technical detail.
What the patent document calls the invention.
A short plain-language summary of the technical disclosure.
Who owns or filed the patent and who is credited as inventor.
Filing, priority, publication, and grant dates set the timeline.
The legal scope of protection — read this for what is actually claimed.
Technology tags used to group this patent with similar filings.
Prior art links and similar publications in this corpus.
Official abstract text for this publication.
Compounds and methods are providing involving RebH variants with improved properties. directed evolution based on random mutagenesis was employed to generate a series of RebH variants. RebH variants with improved thermostability and increased activity at elevated temperatures were generated.
Opening claim text (preview).
The invention claimed is: 1. An isolated RebH variant polypeptide of SEQ ID NO: 1 comprising at least one amino acid substitution, wherein the at least one amino acid substitution results in improved halogenating activity; and wherein the at least one amino acid substitution is selected from the group consisting of S2P, I52T, A58V, M71V, M71T, M71A, M71C, N75K, E96V, D101G, S110P, S110L, F111S, G112S, G112D, L113D, L113N, L114P, S130L, K145M, K145R, N166S, F171I, K187R, D203A, D203G, T213A, V225I, K237E, V256I, T258A, D264G, T283A, L289P, F312L, T322I, T348A, L380F, T394M, F396Y, F396L, R400C, T413A, E423D, A442V, S448P, L453P, F458S, F458L, E461G, F465C, F465L, N467T, N470S, A476T, A476V, V481A, Q494R, T496R, T496A, G504S, and R509Q, wherein the RebH variant polypeptide is at least 85% identical to SEQ ID NO:1. 2. The RebH variant of claim 1 comprising the amino acid substitutions S2P, M71V, K145M, N467T, N470S, and G112S. 3. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates an aromatic substrate. 4. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates a substrate regioselectively. 5. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays improved thermostability over wild-type RebH. 6. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays increased halogenating activity at an elevated temperature. 7. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates the wild-type RebH native substrate tryptophan. 8. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates non-native substrates. 9. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates a substrate and wherein the substrate comprises a molecule selected from the group consisting of indole, tryptoline, 2-methyltryptamine, eleagnine, pinoline, tetrahydroharmine, debromodesformylflustrabromine, yohimbine, evodiamine, pindolol, carazolol, and carvedilol. 10. The RebH variant polypeptide of claim 1 , wherein the polypeptide halogenates using a halogen selected from the group consisting of fluoride, chloride, bromide and iodide. 11. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays a prolonged catalyst lifetime. 12. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays an increased tolerance to proteolysis. 13. The RebH variant polypeptide of claim 1 , wherein the polypeptide displays an increased tolerance to organic solvents. 14. The RebH variant polypeptide of claim 1 , wherein the RebH variant polypeptide halogenates in the absence of a harsh chemical oxidant. 15. A RebH variant polypeptide comprising at least one amino acid substitution at position 2, 52, 58, 71, 75, 96, 101, 110, 111, 112, 113, 114, 130, 145, 166, 171, 187, 203, 213, 225, 237, 256, 258, 264, 283, 289, 312, 322, 348, 380, 394, 396, 400, 413, 423, 448, 453, 455, 458, 461, 465, 467, 470, 476, 481, 494, 496, 504 and/or 509 in SEQ ID NO:1, wherein the RebH variant polypeptide is at least 85% identical to SEQ ID NO:1. 16. The isolated RebH variant polypeptide of claim 1 , wherein the variant comprises at least a S2P substitution.
aromatic (naphthacene C12P29/00) · CPC title
4-Hydroxyphenylacetate 3-monooxygenase (1.14.14.9) · CPC title
Tryptophan 7-halogenase (1.14.14.7) · CPC title
Heterocyclic compounds containing nitrogen atoms as the only ring heteroatoms in the condensed system (alloxazine or isoalloxazine, e.g. riboflavine C12P25/00) · CPC title
Nitrogen as only ring hetero atom · CPC title
Related publications grouped by family.
Answers are generated from the same data shown on this page.